VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00111319 |
Recruitment Status :
Completed
First Posted : May 20, 2005
Last Update Posted : March 26, 2009
|
Sponsor:
Millennium Pharmaceuticals, Inc.
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by:
Millennium Pharmaceuticals, Inc.
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date ICMJE | May 19, 2005 | |||
First Posted Date ICMJE | May 20, 2005 | |||
Last Update Posted Date | March 26, 2009 | |||
Study Start Date ICMJE | December 2004 | |||
Actual Primary Completion Date | July 2007 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures ICMJE |
Time to progression | |||
Original Primary Outcome Measures ICMJE |
Determine whether the addition of VELCADE (bortezomib for injection) to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously untreated multiple myeloma | |||
Change History | ||||
Current Secondary Outcome Measures ICMJE |
Progression-free survival, overall response rate, overall survival, time to first response, duration of response, CR rate, and patient reported outcomes as assessed using the EORTC QLQ-C30, FACIT-F and EQ-5D instruments. | |||
Original Secondary Outcome Measures ICMJE | Not Provided | |||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title ICMJE | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma | |||
Official Title ICMJE | An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma | |||
Brief Summary | The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously untreated multiple myeloma. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
|||
Condition ICMJE | Multiple Myeloma | |||
Intervention ICMJE | Drug: bortezomib | |||
Study Arms ICMJE | Not Provided | |||
Publications * |
|
|||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | Not Provided | |||
Original Enrollment ICMJE |
680 | |||
Study Completion Date ICMJE | Not Provided | |||
Actual Primary Completion Date | July 2007 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study:
Exclusion Criteria: Potential subjects who meet any of the following criteria will be excluded from participating in the study:
|
|||
Sex/Gender ICMJE |
|
|||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | Germany, Russian Federation | |||
Administrative Information | ||||
NCT Number ICMJE | NCT00111319 | |||
Other Study ID Numbers ICMJE | 26866138-MMY-3002 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Current Responsible Party | Clinical Research Monitor, Millennium Pharmaceuticals | |||
Original Responsible Party | Not Provided | |||
Current Study Sponsor ICMJE | Millennium Pharmaceuticals, Inc. | |||
Original Study Sponsor ICMJE | Same as current | |||
Collaborators ICMJE | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |||
Investigators ICMJE |
|
|||
PRS Account | Millennium Pharmaceuticals, Inc. | |||
Verification Date | March 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |